Key Takeaways
- Transition year closes, recovery bets placed: India margins improved 500 bps YoY in Q4 after a transformation program, and April order intake was strong in both India and international markets, setting up a FY26 that management expects to be materially better than FY25.
- Services broke the counter-cyclical script: The expected services uptick during the capex downturn never materialized, but management insists those jobs are delayed, not lost, and expects a recovery in FY26 as customer volumes return.
- Manufacturing footprint overhaul is largely complete: Hyderabad and UK closures are done or on track, Poland is live and delivering a 30% cost advantage on its first orders, and the India transformation program's ₹20 crore of costs are fully absorbed.
- The glass lined cycle is the swing factor: Enough backlog covers H1, but H2 depends on an agrochemical investment recovery that management expects "somewhere in the middle of this quarter."
- What to watch next quarter: Whether the April order intake strength sustains into a backlog build, whether agrochemical conversations convert to orders by August-September, and whether services revenue actually begins to recover.
India Business: Transformation Payoff & Volume Recovery
- Margins already reflecting structural change: India margins hit a level significantly above the prior year despite no material incremental volume, driven by the completed transformation program that shifted Hyderabad production to Gujarat and improved utilization. Management sees 15-16% as achievable for FY26.
- Third shift under consideration: The Gujarat facility is now positioned to add a third shift to handle a large glass lined backlog, a flexibility that did not exist before the Hyderabad closure and load consolidation.
- Volume signals are turning positive: Customers report plants running closer to 80% capacity, and April order intake was very strong, giving the company a much bigger starting backlog than the prior year.
- Heavy engineering is a bright spot: The heavy engineering business catering to oil & gas, petrochemical, power and nuclear performed very well in FY25 and is expected to continue that trajectory in FY26.
- Pharma strength provides a hedge: Hyderabad-based pharmaceutical companies working with GLP-2 manufacturers and peptides drove a large April order win covering both glass lined and non-glass lined equipment.
Tarak Patel: "the first positive sign is at least volumes are coming back."
International Business: Early Green Shoots After a Stagnant Year
- Order intake finally turned in April: After three years of stagnation and a FY25 where services order intake fell drastically from FY22 levels, April delivered a very strong month for international order intake. Management expects to be in a much stronger backlog position by the end of Q1.
- Services broke the recession playbook: The thesis that services would rise when capex fell did not hold: customers cut spare parts budgets amid uncertainty, and larger service jobs were put on hold. Management now argues that as capex and volumes return, services will follow, and the delayed jobs are not lost.
- Tariff uncertainty is the wildcard: Management acknowledges that the current US tariff situation and broader investment uncertainty may have some impact on the international business, even with a good starting backlog.
- Poland is an internal margin play, not a revenue story: The Poland facility will serve as a low-cost manufacturing hub for Mavag (Switzerland) and Mixel (France), with those entities keeping external revenues but at significantly higher margins. The first Mavag order shipped on time with no quality issues at a 30% cost advantage versus Western Europe.
Thomas Kehl: "Some of the bigger service jobs were listed on hold by customers looking at the current situation in the development. But those jobs are not going away, they are delayed, they will come to us later."
Manufacturing Footprint Rationalization
- Three-site consolidation largely complete: The Hyderabad facility was shut down in FY25 with costs taken in Q3, and production moved to Gujarat. The UK facility in Leven is on track for closure in Q2 FY26, with all related costs already absorbed in FY25. The German plant absorbed UK capacity through process improvements, supplemented by products from India.
- Poland ramp-up is the next priority: The Poland site, a 51%-owned startup, is expected to triple its revenue in its first year from internal orders alone. Management intends to ramp production there as quickly as possible over the coming months and quarters.
- Glass lined manufacturing is being decoupled from sales geography: The stated goal is to make manufacturing location a pure supply chain decision based on group capacity, not customer or salesperson preference, to maximize margin capture.
- No major capex needed: Management believes the group needs no real additional investment and will continue to rationalize only if opportunity arises.
Tarak Patel: "The focus, obviously in glass lined, is to improve margins and rationalize manufacturing footprint to a point where the salesperson or the customer should have no say where this product is made."
Demand Cycles: Glass Lined, Agrochemicals & Diversification
- Glass lined backlog covers H1, H2 needs the agrochemical turn: The company has enough glass lined orders for the first half of FY26. The second half depends on whether agrochemical players begin investing in the August-September timeframe, as management expects.
- Agrochemical recovery is a mid-quarter bet: Management expects a recovery "somewhere in the middle of this quarter," citing early conversations from players like PI, SRF and Deccan about next investments.
- Diversification has cushioned the chemical/pharma slowdown: Investments in other European countries, the US, and new segments have made up for shortfalls when pharma and chemicals slowed. Heavy engineering and systems verticals are now the focus for growth, given their much larger addressable markets.
- FGD projects face regulatory timing risk: With the compliance deadline pushed out, new FGD project conversations may slow until the deadline approaches, though advanced-stage conversations continue.
- Flow chemistry positioned for the future: GMM Pfaudler is the only capital goods company in an NCL-led industry alliance developing flow chemistry in India, with products already available and readiness to supply when the technology gains commercial traction.
Tarak Patel: "I do expect a recovery somewhere in the middle of this quarter."
Transformation Program & Leadership
- A formal 12-month transformation program is now launching: Gregory Gelhaus has been appointed Chief Transformation Officer to run a structured program focused on business expansion, operational efficiency, and cross-geography collaboration. Management frames this as a necessary transition from what worked for the last 20 years to what will work for the next 20.
- India transformation costs are fully behind them: The ₹20 crore spent on the India program in FY25 will not carry forward, and the benefits in cost structure and operational excellence are expected to persist.
- Reporting overhaul in progress: Management is reviewing segment reporting and will provide an update during FY26, after declining to break out revenue by glass lined, non-glass lined and mixing on a consolidated basis.
- Vatva expansion is on the horizon: The company believes there is room for growth at Vatva for the next couple of years but anticipates outgrowing it and is actively working on expansion plans to be shared in future calls.
Tarak Patel: "we can't lose sight of the business, because business and financial performance is very important. But at the same time, we need to transition what has worked for us for the last 20 years may not work for us for the next 20 years."
Margins & Financials
- India margin trajectory is set: Q4 India margins were already strong, and management expects them to continue in that range, significantly above the prior year, with 15-16% achievable for FY26. If volumes increase, flow-through should be better given the fixed-cost absorption from the transformation.
- International margins are utilization-dependent: Q4 international margin pressure came from lower utilization. Management expects margins to look "a lot better" if utilization and volumes return.
- FX noise is two-way: The other income loss in Q4 came from unhedgeable inter-company loans between Euro and USD entities, a line that has produced positive impacts in prior quarters.
- No margin guidance given: Management declined to provide targeted margins over the next two years, citing continued uncertainty, especially in the international business. Poland margin details were also declined.
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| India margins | 15-16% achievable | FY26 |
| UK facility closure | Leven site shut down | Q2 FY26 |
| Agrochemical investment recovery | Players expected to start investing | August-September 2025 |
| Services revenue recovery | Delayed jobs return, services come back | FY26 |
| International backlog position | Much stronger position expected | End of Q1 FY26 |
| Poland ramp-up | Production moved and increased | Over the next months and quarters |
| Transformation program | Formal 12-month program under Greg Gelhaus | Next 12 months |
| Segment reporting update | Updated reporting provided | During FY26 |
| Vatva expansion plan | Expansion plan shared | In future calls |
Key Metrics
| Metric | Q4 FY25 |
|---|---|
| Consolidated revenue | ₹807 cr, +9% YoY |
| Consolidated EBITDA | ₹93 cr, 11.5% margin, +4% YoY on margin |
| Consolidated EBITDA margin | 11.5%, up from ~11.1% in Q4 FY24 (per analyst's math) |
| India business revenue | ₹252 cr |
| India business EBITDA | ₹44 cr, 17.4% margin |
| India business EBITDA margin | 17.4%, +500 bps YoY at same revenue levels |
| Consolidated order intake | ₹660 cr |
| FY25 consolidated order intake | ₹3,102 cr, +3% YoY |
| Consolidated backlog (Apr 1, 2025) | ₹1,636 cr |
| India backlog (Apr 1, 2025) | ₹549 cr, +20% YoY |
| FY25 consolidated cash flow from operations | ₹318 cr, improvement of nearly ₹100 cr over FY24 |
| India transformation program cost (FY25) | ₹20 cr total (₹15 cr advisor fees + ₹5 cr Hyderabad closure), none to carry forward |
| Poland cost benefit vs Western Europe | ~30% lower cost base |
| Glass-lined global market share | ~50% |
| India plant utilization | ~80% currently, up from 45–60% earlier |